At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 161 enrolled
Drug / intervention
biphasic insulin aspartdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Titrate-To-Target Study of the Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Mellitus Not Achieving Glycaemic Targets on OADs With / Without Once Daily Basal Insulin Therapy
In Brief
A Phase 4 clinical trial evaluating biphasic insulin aspart for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 161 participants across 1 site.
Detailed Summary
This trial is conducted in Europe. This is a clinical trial investigating the effectiveness and the safety of using biphasic insulin aspart 30 both for initiation and intensification of insulin treatment in type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesTurkey (Türkiye)
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2007
Enrollment StartOct 2007
Primary CompletionJan 2009
TodayJul 2026
First PostedOct 1, 2007
Enrollment StartOct 1, 2007
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 18.8 years ago
Interventions
biphasic insulin aspartdrug
Treat-to-target dose titration scheme (dose individually adjusted), injected s.c. (under the skin)